12:10 PM EDT, 08/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target to $50 from $53, reflecting a 21.0x multiple our new FY 27 (Jun.) EPS estimate, below TECH's 10-year historical forward P/E average. We raise our FY 26 EPS estimate to $2.18 from $1.82 and start FY 27's EPS at $2.38. Bio-Techne ( TECH ) closed out FY 25 with revenue of $1.22B, a 5% Y/Y increase and slightly better than anticipated. This was mainly driven by 5% Y/Y growth in the core Protein Sciences segment ($870M) on solid demand for cell therapy workflow solutions. The decision to divest the Exosome Diagnostics business (expected to close in Q1 FY 26) signals a strategic shift toward focusing on non-CLIA based product lines, which could be beneficial for TECH in the long run, in our view. We think this move could strengthen the company's profitability and allow for increased focus on high-growth areas. Yet, we continue to expect softness in biotech funding in the near term and think the uncertainties surrounding the NIH budget could pressure the spatial biology business in the next quarters.